The development of effective vaccines has helped to eradicate or control the spread of numerous infectious diseases. However, there are many more diseases that have proved more difficult to eliminate using conventional vaccines. The recent innovation of DNA vaccines may provide a “boost” to the development efforts. While the early efforts of DNA vaccines in the clinic were disappointing, the use of in vivo electroporation has helped to provide some basis for optimism. Now, there are several ongoing clinical studies of vaccines against such diseases as malaria, HIV, hepatitis C, and even various types of cancer. This review will highlight three recently published clinical studies using intramuscular DNA administration with electroporation.
DNA vaccines Adjuvants Infectious diseases Oncology Electroporation Intramuscular
This is a preview of subscription content, log in to check access.
Springer Nature is developing a new tool to find and evaluate Protocols. Learn more
Widera G, Austin M, Rabussay D et al (2000) Increased DNA vaccine delivery and immunogenicity by electroporation in vivo. J Immunol 164:4635–4640PubMedGoogle Scholar
Draghia-Akli R, Khan AS, Brown PA et al (2008) Parameters for DNA vaccination using adaptive constant-current electroporation in mouse and pig models. Vaccine 19:5230–5237CrossRefGoogle Scholar
Daud AI, DeConti RC, Andrews S et al (2008) Phase I trial of interleukin-12 plasmid electroporation in patients with metastatic melanoma. J Clin Oncol 26:5896–5903PubMedCrossRefGoogle Scholar
El-Kamary SS, Billington M, Deitz S et al (2012) Safety and tolerability of the Easy Vax clinical epidermal electroporation system in healthy adults. Mol Ther 20:214–220PubMedCrossRefGoogle Scholar
Low L, Mander A, McCann K et al (2009) DNA vaccination with electroporation induces increased antibody responses in patients with prostate cancer. Hum Gene Ther 20: 1269–1278PubMedCrossRefGoogle Scholar
Vasan S, Hurley A, Schlesinger SJ et al (2011) In vivo electroporation enhances the immunogenicity of an HIV-1 DNA vaccine candidate in healthy volunteers. PLoS One 6:e19252PubMedCentralPubMedCrossRefGoogle Scholar